629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster I

Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH)

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA)

Improving outcomes with nivolumab consolidation among older patients =65 with previously untreated primary CNS lymphoma

Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B cell lymphoma A collaborative US bispecific consortium Study

Split dose R CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma DLBCL a Wisconsin oncology network WON study

Impact of extranodal involvement on bispecific antibody BsAb outcomes in patients with large B cell lymphoma LBCL

Real world outcomes of glofitamab therapy in CAR T naive patients with relapsed refractory B cell lymphoma

Epcoritamab epcor monotherapy offers long term disease control in large B cell lymphoma LBCL NHL 1 subgroup analysis in patients with prior chimeric antigen receptor T cell CAR T therapy from the 3 year follow up

Outpatient administration of epcoritamab monotherapy for relapsed refractory diffuse large B cell lymphoma R R DLBCL Results from EPCORE NHL 6 by race and ethnicity

JS203 a CD20×CD3 bispecific antibody demonstrated promising anti cancer activity in patients with relapsed or refractory R R B cell non Hodgkin lymphoma B NHL Updated results from a phase I study

Real world outcomes of glofitamab Glofit plus gemcitabine and oxaliplatin GemOx in Relapsed Refractory R R aggressive B cell lymphoma BCL A multicenter retrospective study from the United States